Street taps Epocrates for research

The research arm of investment banking firm Goldman Sachs will look to promote Epocrates' marketing research services. Financial terms of the three-year agreement were not disclosed.

Hudson Street, a Goldman Sachs business, will seek to connect Epocrates to buyside investors and portfolio managers for use in investigating potential pharma and biotech investments.

“We have a highly targeted panel that they can reach,” said Kirk Loevner, Epocrates chairman and chief executive officer.

Epocrates claims 500,000 active clinician users in its subscriber base. Of those, 200,000 are active US physicians, and 145,000 of those have opted into the marketing research service.

Epocrates, also known for its clinical information and decision support tools, already works with about 150 marketing research firms. They are drawn to the vendor's ability to tap into its physician panel, by specialty and by geography, and get answers to surveys. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.